Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02556437 | Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) | PHASE2 | COMPLETED | 18 | — | — | Jun 1, 2016 | May 1, 2018 | May 17, 2018 | 2 | Denmark |
Measurement of isometric muscle strength of four involved muscle groups
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia |
| Group B | EXPERIMENTAL | 24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) |
| Name | Type | Description |
|---|---|---|
| HyQvia | DRUG | Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection |
| Subcuvia | DRUG | Human immunoglobulin 16% for subcutaneous injection |
Inclusion Criteria: * Age at onset 18 - 65 years. * The presence of asymmetrical limb weakness at onset or motor involvement having a motor nerve distribution in at least two peripheral nerve distributions, predominant upper limb involvement, disabling weakness MRC grade 4 or less in at least one m...